All articles tagged with #mid stage trial
Eli Lilly's experimental obesity drug, eloralintide, shows promising results in mid-stage trials, with significant weight loss and improved health markers, leading to plans for late-stage trials and potential as an alternative to existing therapies.
Insmed's experimental therapy for pulmonary arterial hypertension succeeded in a mid-stage trial, causing shares of competitors Liquidia and United Therapeutics to fall in premarket trading.
Eli Lilly's experimental drug, retatrutide, which targets three hormones, led to 24.2% weight loss in a mid-stage trial, the greatest amount seen yet with an obesity drug. If the weekly injectable drug succeeds in larger Phase 3 trials, it could propel Lilly ahead of competitors in the heated race to supply the most effective obesity treatments.
Viking Therapeutics' experimental obesity drug, VK2735, was safe and helped reduce weight by up to 6% in an early-stage study of about 88 patients. The drugmaker plans to begin a mid-stage trial for the drug in mid-2023, entering the race to develop an obesity treatment market expected to hit $50 billion in sales by 2030. Shares of Viking Therapeutics rose nearly 50% in pre-market trading.